Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.51 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.51 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.50 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.50 |
| ▸ | WDR5 | P61964 | 2/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | PTGIR | P43119 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL560664 | 0.88 | LMNA (0.56) | HTR1DSMN1; SMN2NLRP3LMNAGAA | |
| SCHEMBL8148008 | 0.86 | LMNA (0.52) | HTR1DSMN1; SMN2NLRP3LMNAGAA | |
| SCHEMBL10022889 | 0.86 | LMNA (0.62) | HTR1DSMN1; SMN2NLRP3LMNAGAA | |
| SCHEMBL8146712 | 0.86 | SMN1; SMN2 (0.53) | HTR1DSMN1; SMN2NLRP3LMNAGAA | |
| SCHEMBL8139996 | 0.86 | HTR1D (0.52) | HTR1DSMN1; SMN2NLRP3LMNAGAA | |
| SCHEMBL12139511 | 0.77 | WDR5 (0.47) | HTR1DSMN1; SMN2NLRP3LMNAGAA | |
| SCHEMBL13063071 | 0.77 | LMNA (0.64) | SMN1; SMN2NLRP3LMNAGAAAPOBEC3A | |
| SCHEMBL560655 | 0.77 | ADRA2A (0.55) | SMN1; SMN2NLRP3LMNAGAAAPOBEC3A | |
| SCHEMBL560405 | 0.76 | LMNA (0.71) | SMN1; SMN2NLRP3LMNAGAAAPOBEC3A | |
| SCHEMBL560777 | 0.76 | LMNA (0.56) | SMN1; SMN2NLRP3LMNAGAAAPOBEC3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2303264-B1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS USING IMIDAZOLINE DERIVATIVES | ALLERGAN INC (US) | 2018-04-04 | — | — | EP | claimed |
| US-20150224080-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. | 2015-08-13 | — | — | US | claimed |
| US-9034910-B2 | Methods of treating alpha adrenergic mediated conditions | ALLERGAN, INC. (US) | 2015-05-19 | — | — | US | claimed |
| US-20120165380-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2012-06-28 | — | — | US | claimed |
| US-20120035235-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2012-02-09 | — | — | US | claimed |
| US-8071636-B2 | Methods of treating alpha adrenergic mediated conditions | ALLERGAN, INC. (US) | 2011-12-06 | — | — | US | claimed |
| CN-102099032-A | Methods of treating alpha adrenergic mediated conditions | ALLERGAN INC | 2011-06-15 | — | — | CN | claimed |
| EP-2303264-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | Allergan, Inc. (US) | 2011-04-06 | — | — | EP | claimed |
| WO-2009152052-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2009-12-17 | — | — | WO | claimed |
| US-20090306161-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2009-12-10 | — | — | US | claimed |
| US-20230062049-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230062049-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20200330428-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN INC (US) | 2020-10-22 | — | — | US | disclosed |
| US-20200330428-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN INC (US) | 2020-10-22 | — | — | US | disclosed |
| US-20180344692-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN INC (US) | 2018-12-06 | — | — | US | disclosed |
| US-20090306398-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306161-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306161-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306161-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306398-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306161-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2C, ADRA2A | HTR1D 222/4885SMN1; SMN2 1109/4885NLRP3 3311/4885 |
| US-20230062049-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2A, ADRA2C | HTR1D 230/4885SMN1; SMN2 508/4885NLRP3 3439/4885 |
| US-20150224080-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2A, ADRA2C | HTR1D 230/4885SMN1; SMN2 508/4885NLRP3 3439/4885 |
| US-20090306398-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2C, ADRA2A | HTR1D 222/4885SMN1; SMN2 1109/4885NLRP3 3311/4885 |
| US-20120035235-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2C, ADRA2A | HTR1D 222/4885SMN1; SMN2 1109/4885NLRP3 3311/4885 |
| US-20200330428-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2A, ADRA2C | HTR1D 230/4885SMN1; SMN2 508/4885NLRP3 3439/4885 |
| US-20180344692-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2A, ADRA2C | HTR1D 230/4885SMN1; SMN2 508/4885NLRP3 3439/4885 |
| US-20120165380-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2A, ADRA2C | HTR1D 230/4885SMN1; SMN2 508/4885NLRP3 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.